EOLS

Pre-mercato: 9.87 -0.51 -4.91%

Evolus Inc (EOLS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Evolus Inc Stock (EOLS) Company Profile

Healthcare (1155)

(949) 284-4555

520 NEWPORT CENTER DRIVE, NEWPORT BEACH

@evolusaesthetic

Prossima data di guadagno

Ultimi documenti SEC

EOLS's Discussions on Twitter

Confronta EOLS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
EOLS Evolus Inc	10.38	653.04M	202.09M	-61.69M	-35.64M	-1.08
ZTS Zoetis Inc	146.85	67.28B	9.26B	2.49B	2.30B	5.47
HLN Haleon Plc Adr	10.19	45.61B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	14.93	45.01B	30.25B	1.37B	5.08B	0.4257
TEVA Teva Pharmaceutical Industries Ltd Adr	13.31	15.25B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	284.25	12.77B	2.76B	1.11B	898.10M	22.77

Evolus Inc Stock (EOLS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-04-17	Iniziato	BTIG Research	Buy
2024-01-29	Aggiornamento	Barclays	Equal Weight → Overweight
2022-06-23	Iniziato	Needham	Buy
2022-05-12	Aggiornamento	Barclays	Underweight → Equal Weight
2022-01-20	Aggiornamento	Truist	Hold → Buy
2021-05-06	Aggiornamento	Mizuho	Neutral → Buy
2021-04-08	Reiterato	H.C. Wainwright	Buy
2021-02-24	Downgrade	Truist	Buy → Hold
2020-07-07	Downgrade	Mizuho	Buy → Neutral
2020-02-06	Ripresa	Mizuho	Buy
2019-11-26	Iniziato	SVB Leerink	Outperform
2019-09-05	Ripresa	Mizuho	Buy
2019-06-28	Iniziato	Wells Fargo	Market Perform
2019-06-11	Iniziato	Barclays	Underweight
2019-03-20	Iniziato	SunTrust	Buy
2019-02-14	Iniziato	H.C. Wainwright	Buy
2019-01-29	Iniziato	Stifel	Buy

Mostra tutto

Evolus Inc Borsa (EOLS) Ultime notizie

Evolus Inc Azioni (EOLS) Dati Finanziari

Evolus Inc (EOLS)

Evolus Inc Stock (EOLS) Company Profile

Confronta EOLS con altri titoli

Evolus Inc Stock (EOLS) Upgrades & Downgrades

Evolus Inc Borsa (EOLS) Ultime notizie

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | EOLS Stock News - GuruFocus

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Evolus Strengthens Talent Strategy: 30,579 RSUs Granted to Key New Hires with 2025 Vesting - Stock Titan

Midday Stock Roundup: US Markets Closed for Good Friday - Orange County Business Journal

Evolus announces commercial launch of Evolysse - MSN

BTIG Initiates Coverage of Evolus (EOLS) with Buy Recommendation - Nasdaq

BTIG Initiates Evolus at Buy With $21 Price Target - marketscreener.com

Evolus initiated with a Buy at BTIG - TipRanks

BTIG Initiates Coverage on Evolus (EOLS) with Optimistic Outlook | EOLS Stock News - GuruFocus

Evolus Launches "Drop The F Word" To Redefine Aesthetic Injectables With Evolysse - Nasdaq

Evolus Announces Commercial Launch of Evolysse™ | EOLS Stock New - GuruFocus

Game-Changing Dermal Filler Outperforms Restylane in Clinical Trials: Evolus Expands Portfolio - Stock Titan

Evolus Launches “Drop the F Word” Campaign in Advance of the Com - GuruFocus

Game-Changing Cold-X Technology: Evolus Revolutionizes Injectable Aesthetics with Natural Results - Stock Titan

H.C. Wainwright maintains Buy on Evolus stock with $27 target - Investing.com

H.C. Wainwright maintains Buy on Evolus stock with $27 target By Investing.com - Investing.com Canada

Evolus stock hits 52-week low at $9.22 amid market challenges - Investing.com Canada

Evolus stock hits 52-week low at $9.22 amid market challenges By Investing.com - Investing.com South Africa

Midday Stock Roundup: Evolus, ICU Medical down - Orange County Business Journal

Breaking Down Evolus: 8 Analysts Share Their Views - Benzinga

Investors Give Evolus, Inc. (NASDAQ:EOLS) Shares A 31% Hiding - simplywall.st

Evolus at Needham Conference: Strategic Launch of Evolisse By Investing.com - Investing.com Canada

Evolus at Needham Conference: Strategic Launch of Evolisse - Investing.com

Sandra Beaver: Evolus on Track to Hit $700M Revenue - Orange County Business Journal

Recent 11% pullback isn't enough to hurt long-term Evolus (NASDAQ:EOLS) shareholders, they're still up 170% over 5 years - simplywall.st

Evolus, Inc.: Navigating Financial Challenges Amidst Ongoing Losses and Market Uncertainty - MSN

Evolus CEO David Moatazedi sells $77,512 in stock By Investing.com - Investing.com India

Evolus CEO David Moatazedi sells $77,512 in stock - Investing.com Australia

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference - BioSpace

Evolus Inc (EOLS) Shares Down 4.54% on Mar 25 - GuruFocus

Evolus Leadership Reveals Growth Strategy at Major Healthcare Conference - Stock Titan

Investing in Evolus (NASDAQ:EOLS) five years ago would have delivered you a 216% gain - Yahoo Home

Evolus reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:17 pm EDT - MarketScreener

Evolus director David Moatazedi sells $1.37 million in stock By Investing.com - Investing.com Australia

Evolus Growth Continues: 14 New Employees Join as Company Strengthens Talent Pool - Stock Titan

Evolus to Participate in Canaccord Genuity’s 43rd Annual Growth Conference - Business Wire

Evolus executive Avelar Rui sells $369,867 in stock By Investing.com - Investing.com South Africa

Evolus CFO Sandra Beaver sells $119,242 in company stock By Investing.com - Investing.com South Africa

Evolus chief marketing officer sells $60,124 in common stock By Investing.com - Investing.com South Africa

Evolus CFO Sandra Beaver sells $119,242 in company stock - Investing.com

Evolus director David Moatazedi sells $1.37 million in stock - Investing.com India

Evolus chief marketing officer sells $60,124 in common stock - Investing.com

When the Price of (EOLS) Talks, People Listen - news.stocktradersdaily.com

Trade Alert: Independent Director Of Evolus Karah Parschauer Has Sold Stock - Simply Wall St

Evolus director Parschauer sells $167,465 in common stock By Investing.com - Investing.com India

Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting - Business Wire

Evolus Inc Azioni (EOLS) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a EOLS